Anthem Biosciences, a prominent contract research, development, and manufacturing organisation (CRDMO), has made a remarkable debut on the Indian stock exchanges. The company’s initial public offering (IPO) was keenly awaited, and its listing on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) today, on 21 July 2025, reflects strong investor interest.
Stock Performance on Listing Day
On its debut day, Anthem Biosciences saw a solid opening, with its shares listed at ₹723.05 each on the NSE, marking a 26.85% rise from the IPO price of ₹570. The company’s stock continued its upward trajectory and closed at ₹731.65 on the NSE, a 28.36% premium over the issue price. On the BSE, the stock closed at ₹730.35, a 28.13% premium, signalling investor optimism in the company’s future.
Anthem Biosciences IPO Details
The IPO of Anthem Biosciences opened for subscription on 14 July 2025 and closed on 16 July 2025. The IPO was well-received by the market, with the subscription closing at 63.86 times on the final day. The company set the price band between ₹540 and ₹570 per share for the public offering. The listing today was highly anticipated, as experts predicted significant listing gains, which materialised with the stock debuting well above the issue price.
Company Profile
Anthem Biosciences is a contract research, development, and manufacturing organisation (CRDMO) that focuses on driving innovation in the pharmaceutical sector. The company provides a wide range of services, covering everything from drug discovery to development and manufacturing. Anthem’s strategic emphasis on technology and innovation positions it as a key player in the global biotechnology and pharmaceutical industries.
Listing and Market Sentiment
The strong performance of Anthem Biosciences on its listing day is a positive indicator of market confidence in the company’s future growth potential. Investors are clearly optimistic about the firm’s prospects, driven by its strong market presence and significant growth in the CRDMO sector.
Conclusion
Anthem Biosciences’ debut on the stock exchanges today is a clear sign of strong market confidence. The 28.36% premium to its IPO price reflects the solid demand for its shares, and the positive investor sentiment surrounding the company’s growth strategy. As Anthem Biosciences continues to expand its footprint in drug discovery, development, and manufacturing, it is expected to make further strides in the biotechnology industry.
With today’s strong listing, Anthem Biosciences is now poised to leverage the capital raised through its IPO to fuel future expansion and innovation in the pharmaceutical space. This debut marks a significant milestone in the company’s journey on the Indian stock market.
